AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER (AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER).
Aminosyn II 4.25% in Dextrose 20% provides amino acids for protein synthesis and dextrose as a caloric source. Amino acids are utilized for tissue repair and maintenance, while dextrose provides energy via glycolysis and oxidative phosphorylation.
| Metabolism | Amino acids are metabolized via transamination, deamination, and incorporation into proteins. Dextrose is metabolized via glycolysis, the Krebs cycle, and oxidative phosphorylation. Both are ultimately oxidized to carbon dioxide and water. |
| Excretion | Amino acids undergo metabolism; excess nitrogen is excreted renally as urea (80-90%), with minimal biliary/fecal elimination (<5%). Dextrose is metabolized. |
| Half-life | Not applicable; components are endogenous substances. Clinical effect (nitrogen balance) persists 4-6 hours post-infusion. |
| Protein binding | Amino acids: minimal (<10%), mainly albumin. Dextrose: not bound. |
| Volume of Distribution | Amino acids: 0.5-0.8 L/kg (total body water). Dextrose: 0.2 L/kg (extracellular fluid). |
| Bioavailability | 100% IV; not administered via other routes. |
| Onset of Action | Immediate upon IV infusion; metabolic effects begin within minutes. |
| Duration of Action | 4-6 hours for nitrogen balance effect; continuous infusion required to maintain anabolic state. |
Intravenous infusion of 500 mL to 1 L per day. Typical rate: 1-2 mL/min (60-120 mL/hr). Adjust based on caloric and fluid requirements.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR 50-80 mL/min: use with caution; monitor electrolytes. For GFR <50 mL/min: avoid due to risk of fluid overload and electrolyte imbalances; consider renal replacement therapy. |
| Liver impairment | Child-Pugh Class A: no adjustment. Class B: reduce to 50% of standard dose. Class C: contraindicated due to risk of hepatic encephalopathy. |
| Pediatric use | Child: 2-3 g/kg/day of amino acids (based on IBW) and 10-20 g/kg/day of dextrose. Neonates: 1-2 g/kg/day of amino acids, adjust dextrose to maintain euglycemia. |
| Geriatric use | Initiate at 25-50% of standard adult dose; titrate slowly based on renal function and fluid status. Monitor for volume overload and electrolyte disturbances. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER (AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER).
| Breastfeeding | Excreted into breast milk; dextrose and amino acids are normal milk components. M/P ratio not reported. Generally considered compatible with breastfeeding. |
| Teratogenic Risk | No known teratogenic risk in first trimester; essential amino acids and dextrose are required for fetal growth. Use only if clearly needed. Second and third trimester: No specific fetal risks, but monitor for maternal hyperglycemia and electrolyte imbalances. |
■ FDA Black Box Warning
Aminosyn II 4.25% in Dextrose 20% is not for intravenous administration directly. It is intended as a component of total parenteral nutrition (TPN) and must be mixed with electrolytes, vitamins, and minerals prior to infusion. Do not administer unless solution is clear and container is undamaged.
| Serious Effects |
["Severe metabolic acidosis","Hypersensitivity to any component","Severe hepatic failure","Severe renal failure without dialysis","Hyperglycemia or hyperosmolar states"]
| Precautions | ["Risk of hyperglycemia, especially in diabetic or stressed patients","Fluid overload and electrolyte imbalances","Hepatic and renal impairment may require dose adjustment","Monitor for signs of infection at IV site","May cause metabolic acidosis or azotemia"] |
| Food/Dietary | Do not administer with any oral food or enteral feedings as this is for peripheral/parenteral nutrition only. No dietary restrictions apply as the drug is used in place of oral intake. Avoid concomitant use of oral hypoglycemics due to dextrose content. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood glucose, serum electrolytes, and fluid balance. Fetal monitoring as per standard obstetrical care; no special fetal monitoring required. |
| Fertility Effects | No known adverse effects on fertility. |
| Clinical Pearls | Monitor serum electrolytes, blood glucose, and fluid balance frequently. Administer via central line due to high osmolarity (~1250 mOsm/L). Check for dextrose-induced hyperglycemia; may require insulin. Do not withdraw for lab sampling from same line. Use with caution in renal/hepatic impairment. Do not confuse with TPN formulations containing lipids. |
| Patient Advice | This solution provides nutrition and fluids directly into a large vein. · Notify your healthcare provider if you experience headache, confusion, or swelling. · You may need frequent blood tests to monitor sugar, electrolyte, and kidney function. · Do not stop the infusion abruptly to avoid low blood sugar. · Inform your doctor about all medications and supplements you take. · Report any signs of infection at the infusion site: redness, warmth, or drainage. |